Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
Medicine (Baltimore). 2022 Feb 11;101(6):e28777. doi: 10.1097/MD.0000000000028777.
Coronavirus disease 2019 (COVID-19) is an acute respiratory infectious disease that is often accompanied by diarrhea, patients with symptoms such as diarrhea are more likely to develop severe pneumonia, while diarrhea is the most prominent among atypical symptoms. The incidence of diarrhea in COVID-19 patients is 2.0% to 49.5%. Moxibustion has been proven to have a therapeutic effect on diarrhea; however, there is no high-quality evidence on moxibustion for diarrhea in COVID-19 patients. This study was designed to evaluate the effectiveness and safety of moxibustion for the treatment of diarrhea in patients with COVID-19.
Randomized controlled trials from December 2019 to December 2021 will be included without restrictions on language or publication date. PubMed, EMBASE, Cochrane Library, Web of Science, Chinese Biomedical Databases, China National Knowledge Infrastructure, Wanfang database, and VIP database will be searched. Two researchers will independently select studies, extract data and evaluate study quality. Cochrane risk of bias tool for randomized trials will be used to assess the risk of bias of included studies. Statistical analyses will be performed using the Review Manager V.5.3 and stata 14.0.
The results of this meta-analysis will be submitted to a peer-reviewed journal for publication.
This study will provide evidence for whether moxibustion therapy is beneficial to the treatment of diarrhea in COVID-19.
Ethical approval is not required for this study. The systematic review will be published in a peer-reviewed journal, presented at conferences, and shared on social media platforms. This review would be disseminated in a peer-reviewed journal or conference presentations.
CRD42022302933.
2019 年冠状病毒病（COVID-19）是一种急性呼吸道传染病，常伴有腹泻，有腹泻症状的患者更易发展为重症肺炎，而腹泻是最突出的非典型症状之一。COVID-19 患者腹泻的发生率为 2.0%~49.5%。艾灸已被证明对腹泻有治疗作用；然而，对于 COVID-19 患者的腹泻，艾灸尚无高质量证据。本研究旨在评估艾灸治疗 COVID-19 患者腹泻的有效性和安全性。
纳入 2019 年 12 月至 2021 年 12 月的随机对照试验，语言和出版日期不限。检索 PubMed、EMBASE、Cochrane 图书馆、Web of Science、中国生物医学文献数据库、中国知网、万方数据库和 VIP 数据库。两名研究人员将独立选择研究、提取数据和评估研究质量。采用 Cochrane 随机对照试验偏倚风险工具评估纳入研究的偏倚风险。统计分析将使用 Review Manager V.5.3 和 stata 14.0 进行。
本荟萃分析的结果将提交给同行评议期刊发表。
本研究将为艾灸疗法是否有益于 COVID-19 患者腹泻的治疗提供证据。
本研究不需要伦理批准。系统评价将发表在同行评议期刊上，在会议上展示，并在社交媒体平台上分享。本综述将发表在同行评议期刊或会议报告中。
PROSPERO 注册号：CRD42022302933。
